Current pneumonia vaccines face a critical weakness: they protect against bloodstream infections but leave the lungs vulnerable to respiratory invasion. This gap becomes deadly during flu season when secondary bacterial pneumonia kills thousands annually, particularly among older adults whose immune systems struggle to mount rapid lung defenses.
A novel "prime-spike" vaccination approach addresses this vulnerability by combining traditional muscle injection with a follow-up nasal spray. Researchers used outer membrane vesicles carrying pneumococcal surface protein A (PspA) for the initial shots, then delivered pure PspA protein directly into nasal passages. This dual-route strategy achieved near-complete protection against two dangerous pneumonia strains in laboratory models, including during influenza co-infections that typically overwhelm standard vaccines.
The nasal component proved crucial for establishing what immunologists call "tissue-resident memory" - specialized immune cells that patrol lung tissues rather than circulating through blood. These stationed defenders included memory B cells producing targeted antibodies and T cells secreting inflammatory signals like interferon-gamma and IL-17A. Laboratory tests confirmed these antibodies effectively triggered immune cells to engulf and destroy clinical pneumonia isolates.
This represents a potentially transformative shift from systemic to localized immunity. While current pneumococcal vaccines excel at preventing invasive disease, they leave mucosal surfaces exposed. The prime-spike approach could finally bridge this protection gap, offering particular promise for vulnerable populations during respiratory virus seasons when bacterial superinfections pose the greatest threat.